Antipyretics to enhance tolerability of vesicle-based vaccines
OwnerAlan Kimura, Peter Dullinventors
Life of this patent
Estimating the term…
Abstract
A method for immunising a human subject, wherein the subject receives (i) an immunogenic composition comprising bacterial vesicles and (ii) an antipyretic, and wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other. Paracetamol significantly reduces fever rates without negatively affecting the immunogenicity either of a meningococcal vesicle vaccine or of concomitantly-administered antigens.
Claims37
A method for immunising a human subject, wherein the subject receives (i) an immunogenic composition comprising bacterial vesicles and (ii) an antipyretic, and wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other.
An antipyretic and an immunogenic composition comprising bacterial vesicles, for combined use in a method of immunising a human subject, wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other.
In a method for immunising a human subject by administering an immunogenic composition comprising bacterial vesicles, an improvement consisting of administering an antipyretic to the subject within 24 hours of administering the immunogenic composition.
A combination of (i) an antipyretic and (ii) an immunogenic composition comprising bacterial vesicles, for simultaneous, separate or sequential administration, wherein components (i) and (ii) are administered within 24 hours of each other.
A kit comprising (i) an antipyretic and (ii) an immunogenic composition comprising bacterial vesicles.
A package comprising (i) an immunogenic composition comprising bacterial vesicles and (ii) an information leaflet (a) containing written instructions that an antipyretic may be administered to a subject within 24 hours of their receiving the immunogenic composition and/or (b) instructing a subject or physician to administer an antipyretic to the subject if the subject develops a fever after receiving the immunogenic composition.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the antipyretic is administered (i) no more than 2 hours before the immunogenic composition (ii) at the same time as the immunogenic composition or (iii) no more than 2 hours after the immunogenic composition.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the subject is less than 1 year old.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the vesicles are meningococcal outer membrane vesicles.
A method for immunising a human subject, wherein the subject receives (i) an immunogenic composition comprising a meningococcal fHbp antigen and (ii) an antipyretic, and wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other.
An antipyretic and an immunogenic composition comprising a meningococcal fHbp antigen, for combined use in a method of immunising a human subject, wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other.
In a method for immunising a human subject by administering an immunogenic composition comprising a meningococcal fHbp antigen, an improvement consisting of administering an antipyretic to the subject within 24 hours of administering the immunogenic composition.
A combination of (i) an antipyretic and (ii) an immunogenic composition comprising a meningococcal fHbp antigen, for simultaneous, separate or sequential administration, wherein components (i) and (ii) are administered within 24 hours of each other.
A kit comprising (i) an antipyretic and (ii) an immunogenic composition comprising a meningococcal fHbp antigen.
A package comprising (i) an immunogenic composition comprising a meningococcal fHbp antigen and (ii) an information leaflet (a) containing written instructions that an antipyretic may be administered to a subject within 24 hours of their receiving the immunogenic composition and/or (b) instructing a subject or physician to administer an antipyretic to the subject if the subject develops a fever after receiving the immunogenic composition.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the combination of an antipyretic and an immunogenic composition is administered to a subject 2 or more times.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the immunogenic composition includes an aluminium salt adjuvant.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the immunogenic composition is administered by intramuscular injection.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the antipyretic is acetaminophen.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the antipyretic is administered before the immunogenic composition.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the immunogenic composition and the antipyretic are administered within 1 hour of each other.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the subject receives the immunogenic composition once and the antipyretic at least twice within a 24 hour period.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the antipyretic will be administered orally.
The method, composition, improvement, combination, kit or package of any preceding claim, wherein the subject also receives an immunogenic composition which does not comprise bacterial vesicles.
Dependencies are inferred from the claim text.